SynthesisBMC musculoskeletal disorders2025
Efficacy and safety of denosumab in treatment of osteoporosis in patients with rheumatoid arthritis: a meta-analysis and systematic review.
Synthesis in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis meta-analysis aims to assess the efficacy and safety of denosumab in treating osteoporosis (OP) in patients with rheumatoid arthritis (RA).
methodsWe conducted a comprehensive search in databases including PubMed, Embase and Cochrane Library for studies on denosumab's effectiveness in treating OP in RA patients from their inception until 2023. Two researchers independently screened the retrieved literature, and the methodological quality of the included studies was evaluated using the Cochrane 5.1 bias risk assessment tool. Statistical analysis was performed using STATA 15.1.
resultsA total of 1441 patients from 9 articles, meeting the specified criteria, were included, with 762 in the experimental group and 679 in the control group. The pooled results suggest that following the treatment of osteoporosis in patients with rheumatoid arthritis, both bone mineral density (BMD) and bone erosion score (BES) exhibit notable increases with denosumab in comparison to biological agent therapy. Moreover, the modified total Sharp score (mTSS), joint space narrowing (JSN), and BES demonstrate significantly higher improvements subsequent to denosumab therapy for osteoporosis in rheumatoid arthritis patients, as opposed to receiving a placebo. However, there is no significant difference between denosumab and placebo treatment for osteoporosis in patients with RA in terms of serious adverse events.
conclusionIn conclusion, compared to the control group, denosumab treatment significantly increased lumbar spine BMD in RA patients who had not received BPs treatment. Additionally, it reduced joint mTSS, JSN, and BES, alleviated joint space narrowing, and inhibited bone erosion, providing maximal joint protection and maintaining joint function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.